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1. NTHL1Mutation Causes Adenomatous Polyposis and lidocaine patch), and controls were diabetic individuals who were not
Colorectal Cancer
Patients with adenomatous polyposis have higher risk for colorectal
cancer; however causative genes remain unknown in a considerable
fraction of these patients. On behalf of his collaborators, Robbert
Weren (Nijmegen, Netherlands) presented whole-exome sequencing
data from 51 individuals (of 48 families) with adenomatous polyposis.
They identiﬁed a homozygous germline nonsense mutation in the
base-excision repair (BER) gene NTHL1 in 7 affected individuals from 3
unrelated families. These patients were homozygous for the germline
mutation, and showed recessive inheritance of the adenomatous
polyposis phenotype, whereas in controls, this mutation was only
found in a heterozygous state. Thus, this newNTHL1 genemutation pre-
disposes the homozygous individuals to a novel subtype of BER-
associated adenomatous polyposis and colorectal cancer.
2. Whole Genome Sequencing Proﬁling in Autism
Previous genetic studies have identiﬁed hundreds of susceptibility
loci for autism spectrum disorder (ASD). In this presentation, Ryan
Yuen (Toronto, Canada) and his collaborators used whole-genome se-
quencing of 85 quartet families (parents and twoASD-affected siblings),
consisting of 170 individuals with ASD, to generate a comprehensive
data resource encompassing all classes of genetic variation and accom-
panying phenotypes of ASD. They found that more than two-thirds of
the affected siblings carried different ASD-relevant mutations. These
siblingswith discordantmutations tended to demonstratemore clinical
variability than those who shared a risk variant. This study reiterates
that ASD is genetically heterogeneous, and whole-genome sequencing
is necessary to delineate all genic and nongenic susceptibility variants
in research and in clinical diagnostics. The study has been expanded to
include 200 additional ASD families, and results are awaited.
3. Genome-wide Association Study Reveals Genetic Involvement
with Diabetic Neuropathic Pain
Neuropathic pain affects around 1 in 4 diabetic patients in the UK,
however genetic contributors are unknown. Here, Weihua Meng
(Dundee, UK) and colleagues investigated the genetic information and
the prescription records of 6927 diabetic individuals from the Genetics
of Diabetes Audit and Research Tayside (GoDARTS) project. Cases of
neuropathic pain were deﬁned as diabetic patients with a multiple
prescription history of one or more drugs speciﬁc for neuropathic pain
(duloxetine, gabapentin, pregabalin, capsaicin cream/patch andhttp://dx.doi.org/10.1016/j.ebiom.2015.06.014
2352-3964/© 2015 Published by Elsevier B.V. This is an open access article under the CC BY-NCprescribed any of these drugs, nor amitriptyline, carbamazepine, or nor-
triptyline. The authors identiﬁed 961 diabetic neuropathic pain cases
and 3260 diabetic controls. Genome-wide association analyses revealed
a cluster in the Chr1p35.1 (ZSCAN20-TLR12P) at rs71647933 in female
patients, and a cluster in the Chr8p23.1 next to HMGB1P46 at
rs6986153 in male patients, which were associated with neuropathic
pain. This study provides evidence for sex-speciﬁc, genetic involvement
with diabetic neuropathic pain.
4.MCEMP1 Expression as a Stroke Biomarker
Stroke is a leading cause of death and functional disability, and a
rapid blood-based diagnostic testmay expedite diagnosis and prognosis
of acute stroke. As part of the INTERSTROKE study, Kripa Raman from
Guillaume Pare's group (Hamilton, Canada) assessed 302 stroke case
and controls for transcriptome-wide peripheral blood gene expression
using the Illumina HumanRef-8 v4 bead chip. Signiﬁcantly expressed
genes were validated using qPCR in another cohort of 62 individuals.
The authors found thatMCEMP1 gene expression was sufﬁcient to dis-
tinguish between stroke cases and controls (AUC=0.812), and also dif-
ferentiated between ischemic and hemorrhagic stroke cases (AUC =
0.783). Furthermore, MCEMP1 expression was signiﬁcantly associated
with 1-month outcome, measured as Modiﬁed Rankin Score (MRS),
after adjustment for available risk factors, primary stroke type and base-
line MRS. Peripheral blood expression ofMCEMP1may have utility as a
diagnostic test for acute stroke, in distinguishing ischemic stroke from
intracerebral hemorrhage and a prognostic biomarker of outcome.
5.MTRNR2L12 as a Marker of Early Dementia in Down Syndrome
It has been reported that autopsied brain tissues of adult patients
with Down syndrome contain histological changes identical with
those observed in Alzheimer's disease. Interestingly, many adults with
Down syndrome never presentwith dementia, whereas in some others,
Alzheimer's disease-like dementia develops in the ﬁfth decade of life.
Miroslaw Bik-Multanowski (Krakow, Poland) and his collaborators per-
formed cognitive assessment in a cohort of 48 adults with Down syn-
drome, with subsequent microarray-based analysis of whole-genome
expression in leukocytes. Microarray data analysis revealed signiﬁcant
differences between groups of younger patients with severe cognitive
disability and older patients without dementia with regard to expres-
sion of MTRNR2L12 gene, which is known to be associated with
Alzheimer's disease. These ﬁndings suggest a protective role of
MTRNR2L12 in the development of early Alzheimer's disease-like-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
618 D.H. Le / EBioMedicine 2 (2015) 617–618dementia in adultswithDown syndrome. Further studies arewarranted
to evaluate potential usefulness of this marker in patients with
Alzheimer's disease.
6. NGS Panel for Diagnosis of Early and Severe Forms of Polycystic
Kidney Disease
Polycystic kidney disease (PKD) is one of the most common poten-
tially life-threatening human genetic disorders, and early and severe
PKD occur in patients with the autosomal recessive form (ARPKD) and
2–5% of the autosomal dominant form (ADPKD). PKD is highly geneti-
cally heterogeneous, making genetic testing difﬁcult. Carsten Bergmann
(Ingelheim, Germany) and colleagues have developed a novel custom-
ized sequence capture-based NGS panel for PKD that targets 95 genes.The authors analyzed a cohort of 308 patients with early and severe
PKD, and found that the majority of patients carried mutations in
PKD1, PKD2 and PKHD1, however a subgroup harbored mutations in
genes related to other ciliopathies (e.g., nephronophthisis, Joubert,
Meckel, and Bardet–Biedl syndrome). They demonstrated that PKD1 is
a driver for early and severemanifestations in familieswith ADPKD. No-
tably, mutations in both ADPKD genes (PKD1 and PKD2) can also be
identiﬁed in ARPKD patients. The authors proposed a dosage-sensitive
model for early and severe forms of PKD, and their NGS panel allows
parallel analysis of all disease genes including PKD1which plays a deci-
sive role in cyst initiation. An accurate genetic diagnosis is crucial for ge-
netic counseling, prenatal diagnostics and the clinical management of
patients.
